The company used two real-world data sets from Israel, both of which showed evidence that an additional booster increases immunogenicity and lowers rates of confirmed infections and severe illness, according to the release.
Pfizer also said “emerging evidence” suggests effectiveness against both symptomatic COVID-19 and severe infection wanes three to six months after initial booster dosage.
“These early studies indicate that an additional booster dose of the Pfizer-BioNTech COVID-19 vaccine administered at least four months after an initial booster dose could restore antibody titers to peak post-third dose titer levels, improve protection against both infection and severe disease in individuals 60 years of age and older in Israel, and have a similar safety profile to that of previous doses,” the news release said.
Editor’s note: This piece was updated March 16 to reflect a news release from Pfizer.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
